Literature DB >> 10642585

Expression of vascular endothelial growth factor receptors in the human endometrium: modulation during the menstrual cycle.

G Meduri1, P Bausero, M Perrot-Applanat.   

Abstract

Angiogenesis is fundamental for human endometrial development and differentiation necessary for implantation. These vascular changes are thought to be mediated by the vascular endothelial growth factor (VEGF), whose specific receptors have not been examined in detail thus far. We conducted the present study to determine, by immunocytochemistry and computerized image analysis of the functionalis, the expression and modulation of the receptors Flk-1/KDR and Flt-1, which mediate VEGF effects on endothelial mitogenicity, chemotaxis, and capillary permeability. VEGF receptors are expressed mainly in endometrial endothelial cells, with variations of intensity and number of stained capillaries related to the phase of the cycle. The number of capillaries immunostained for Flk-1/KDR was maximal in the proliferative phase (ratio Flk-1/CD34: 1), twice as high as the number of Flt-1-expressing capillaries (ratio Flt-1/CD34: 0.47). The staining intensity for Flk-1 decreased during the late proliferative and early secretory phases, to increase again in the midsecretory period. The number of Flt-1-labeled capillaries was about 2-fold higher in the secretory than in the proliferative phase; however, the proportion of Flt-1-positive cells did not change, owing to the associated increase in vascular density that characterizes progression of the functionalis from the proliferative to the secretory stage. The staining intensity for Flt-1 was higher during the late proliferative and secretory phases (especially in the midsecretory phase) and the premenstrual period. In contrast, the proportion of capillaries expressing Flk-1/KDR decreased in the secretory phase (ratio Flk-1/Von Willebrand factor: 0.55). Enhanced expression of Flk-1/KDR, and of Flt-1, on narrow capillary strands at the beginning of and during the proliferative phase may account for the rapid capillary growth associated with endometrial regeneration following menstrual shedding. The high coexpression of Flk-1/KDR and Flt-1 observed on capillaries during the midsecretory period correlates with an increase of endometrial microvascular density and of permeability characteristic of this phase of the cycle, which is a prerequisite for implantation. Finally, strong expression of Flt-1, but not Flk-1/KDR, was observed on dilated capillaries during the premenstrual period and the late proliferative phase, suggesting preferential association of Flt-1 with nonproliferating capillaries at those times; activation of this receptor by VEGF could be involved in premenstrual vascular hyperpermeability, edema, and extravasation of leukocytes. In addition to the endothelial localization, we found that epithelial cells expressed Flt-1 and Flk-1/KDR. We conclude that Flt-1 and Flk-1/KDR in the functionalis are modulated in parallel or independently according to the phase of the cycle, and that these changes are responsible for VEGF actions on endometrial vascular growth and permeability. The molecular mechanisms concerning these regulations will require further investigation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10642585     DOI: 10.1095/biolreprod62.2.439

Source DB:  PubMed          Journal:  Biol Reprod        ISSN: 0006-3363            Impact factor:   4.285


  20 in total

1.  Platelet-rich plasma or blood-derived products to improve endometrial receptivity?

Authors:  Adriana Bos-Mikich; Marcelo O Ferreira; Ricardo de Oliveira; Nilo Frantz
Journal:  J Assist Reprod Genet       Date:  2019-01-04       Impact factor: 3.412

Review 2.  The endometrial lymphatic vasculature: function and dysfunction.

Authors:  Jane E Girling; Peter A W Rogers
Journal:  Rev Endocr Metab Disord       Date:  2012-12       Impact factor: 6.514

3.  Vascular repair after menstruation involves regulation of vascular endothelial growth factor-receptor phosphorylation by sFLT-1.

Authors:  M D Graubert; M A Ortega; B Kessel; J F Mortola; M L Iruela-Arispe
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

4.  A dynamic shift of VEGF isoforms with a transient and selective progesterone-induced expression of VEGF189 regulates angiogenesis and vascular permeability in human uterus.

Authors:  Magali Ancelin; Hélène Buteau-Lozano; Geri Meduri; Mary Osborne-Pellegrin; Sylvie Sordello; Jean Plouët; Martine Perrot-Applanat
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-23       Impact factor: 11.205

5.  Comparative effects of 17beta-estradiol and phytoestrogens in the regulation of endometrial functions in the rodent uterus.

Authors:  D Gallo; G F Zannoni; M Fabrizi; I De Stefano; E Mantuano; G Scambia
Journal:  J Endocrinol Invest       Date:  2008-01       Impact factor: 4.256

Review 6.  Oxidative stress in angiogenesis and vascular disease.

Authors:  Young-Woong Kim; Tatiana V Byzova
Journal:  Blood       Date:  2013-12-03       Impact factor: 22.113

Review 7.  Regulation of human endometrial function: mechanisms relevant to uterine bleeding.

Authors:  Hilary O D Critchley; Rodney W Kelly; David T Baird; Robert M Brenner
Journal:  Reprod Biol Endocrinol       Date:  2006       Impact factor: 5.211

8.  Differential expression of Na+/H+-exchanger (NHE-1, 2, and 4) proteins and mRNA in rodent's uterus under sex steroid effect and at different phases of the oestrous cycle.

Authors:  Khadijeh Gholami; Sekaran Muniandy; Naguib Salleh
Journal:  Biomed Res Int       Date:  2013-02-11       Impact factor: 3.411

9.  Active immunization against the vascular endothelial growth factor receptor flk1 inhibits tumor angiogenesis and metastasis.

Authors:  Yiwen Li; Mei-Nai Wang; Hongli Li; Karen D King; Rajiv Bassi; Haijun Sun; Angel Santiago; Andrea T Hooper; Peter Bohlen; Daniel J Hicklin
Journal:  J Exp Med       Date:  2002-06-17       Impact factor: 14.307

Review 10.  Biology of primate relaxin: a paracrine signal in early pregnancy?

Authors:  Eric S Hayes
Journal:  Reprod Biol Endocrinol       Date:  2004-06-16       Impact factor: 5.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.